AU2001254561A1 - Immunizing against hiv infection - Google Patents
Immunizing against hiv infectionInfo
- Publication number
- AU2001254561A1 AU2001254561A1 AU2001254561A AU5456101A AU2001254561A1 AU 2001254561 A1 AU2001254561 A1 AU 2001254561A1 AU 2001254561 A AU2001254561 A AU 2001254561A AU 5456101 A AU5456101 A AU 5456101A AU 2001254561 A1 AU2001254561 A1 AU 2001254561A1
- Authority
- AU
- Australia
- Prior art keywords
- hiv infection
- against hiv
- immunizing against
- immunizing
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20001100P | 2000-04-27 | 2000-04-27 | |
US60200011 | 2000-04-27 | ||
PCT/CA2001/000577 WO2001082962A2 (en) | 2000-04-27 | 2001-04-25 | Immunizing against hiv infection |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001254561A1 true AU2001254561A1 (en) | 2001-11-12 |
Family
ID=22739938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001254561A Abandoned AU2001254561A1 (en) | 2000-04-27 | 2001-04-25 | Immunizing against hiv infection |
Country Status (8)
Country | Link |
---|---|
US (4) | US20040013684A1 (en) |
EP (1) | EP1280551B1 (en) |
AU (1) | AU2001254561A1 (en) |
CA (1) | CA2416725A1 (en) |
DE (1) | DE60125927T2 (en) |
DK (1) | DK1280551T3 (en) |
ES (1) | ES2282251T3 (en) |
WO (1) | WO2001082962A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
EP1418940A4 (en) | 2000-03-02 | 2006-09-20 | Univ Emory | Dna expression vectors and methods of use |
CA2407303A1 (en) * | 2000-04-28 | 2001-11-08 | Genoveffa Franchini | Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines |
DE60234018D1 (en) | 2001-03-08 | 2009-11-26 | Univ Emory | MVA-EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES |
AU2004231464B2 (en) * | 2003-03-26 | 2010-08-05 | Wyeth | Immunogenic composition and methods |
US20060257416A1 (en) * | 2003-06-13 | 2006-11-16 | Palmowski J M | Materials and methods for improved vaccination |
CA2791025A1 (en) * | 2010-02-25 | 2011-09-01 | Duke University | Method of inducing the production of protective anti-hiv-1 antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294322B1 (en) * | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
CN1111540C (en) * | 1993-06-09 | 2003-06-18 | 康诺特实验室有限公司 | Placed in-line synthetic HIV-1 peptide class |
US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
US6395714B1 (en) * | 1999-02-24 | 2002-05-28 | Aventis Pasteur Limited | Expressing gp140 fragment of primary HIV-1 isolate |
-
2001
- 2001-04-25 DK DK01927532T patent/DK1280551T3/en active
- 2001-04-25 CA CA002416725A patent/CA2416725A1/en not_active Abandoned
- 2001-04-25 EP EP01927532A patent/EP1280551B1/en not_active Expired - Lifetime
- 2001-04-25 WO PCT/CA2001/000577 patent/WO2001082962A2/en active IP Right Grant
- 2001-04-25 US US10/257,962 patent/US20040013684A1/en not_active Abandoned
- 2001-04-25 DE DE60125927T patent/DE60125927T2/en not_active Expired - Lifetime
- 2001-04-25 ES ES01927532T patent/ES2282251T3/en not_active Expired - Lifetime
- 2001-04-25 AU AU2001254561A patent/AU2001254561A1/en not_active Abandoned
- 2001-04-27 US US09/842,883 patent/US20020051770A1/en not_active Abandoned
-
2005
- 2005-06-01 US US11/140,930 patent/US20050287174A1/en not_active Abandoned
-
2008
- 2008-09-18 US US12/233,021 patent/US20090142373A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2416725A1 (en) | 2001-11-08 |
US20040013684A1 (en) | 2004-01-22 |
US20090142373A1 (en) | 2009-06-04 |
US20020051770A1 (en) | 2002-05-02 |
DK1280551T3 (en) | 2007-05-21 |
DE60125927D1 (en) | 2007-02-22 |
EP1280551B1 (en) | 2007-01-10 |
US20050287174A1 (en) | 2005-12-29 |
WO2001082962A3 (en) | 2002-03-21 |
ES2282251T3 (en) | 2007-10-16 |
DE60125927T2 (en) | 2007-10-18 |
WO2001082962A2 (en) | 2001-11-08 |
EP1280551A2 (en) | 2003-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002236159A1 (en) | Immunogenic complex | |
AU2002224520A1 (en) | A cannula | |
AU2001227916A1 (en) | Earplug | |
AU2002223827A1 (en) | Well treatment | |
AU2001274548A1 (en) | Syringe | |
AU2002254558A1 (en) | Novel vaccine | |
AU2001280598A1 (en) | Anti-occlusion catheter | |
AU1285300A (en) | Hiv vaccine | |
AU2002217748A1 (en) | Shrouded bomb | |
AU1408300A (en) | Hiv infection inhibitors | |
AU6594401A (en) | 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines | |
AU2001289831A1 (en) | Medicaments against viral infections | |
AU2001240791A1 (en) | Sequence | |
AU2002212914A1 (en) | Autofocusing | |
AU2001254561A1 (en) | Immunizing against hiv infection | |
AUPQ948800A0 (en) | A vaccine strategy | |
AU6158700A (en) | Vaccine | |
AUPR030800A0 (en) | Immunomodulatory preparation | |
AU2002239395A1 (en) | Hiv treatment with benzimidazoles | |
AU2001267541A1 (en) | Vaccine composition | |
AU5811600A (en) | Vaccine | |
AU5274099A (en) | Hiv vaccine | |
AU2002211324A1 (en) | Oxidoreductases | |
AU2000279374A1 (en) | Secure syringe | |
AU2001280820A1 (en) | Telecommunication-based common contracting |